title: A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
abstract: The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m² preceded by escalating doses of docetaxel 60 mg/m² (75, 90, 100 mg/m²) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m² with oxaliplatin 130 mg/m².
authors.affiliation: USC/Norris Comprehensive Cancer Center, Oncology, Los Angeles, CA, USA. iqbal@usc.edu
authors.forename: Syma
authors.initials: S
authors.lastname: Iqbal
authors.forename: Heinz-Josef
authors.initials: HJ
authors.lastname: Lenz
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
authors.forename: Stephen I
authors.initials: SI
authors.lastname: Shibata
authors.forename: Susan
authors.initials: S
authors.lastname: Groshen
authors.forename: Timothy W
authors.initials: TW
authors.lastname: Synold
authors.forename: Edward M
authors.initials: EM
authors.lastname: Newman
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000503:physiopathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D009503:Neutropenia / Q000139:chemically induced / Q000503:physiopathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077150:Oxaliplatin; D012720:Severity of Illness Index; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D050257:Tubulin Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D043823:Taxoids; D050257:Tubulin Modulators; D000077150:Oxaliplatin; D000077143:Docetaxel